Publikationen von Markus Dietlein

Richter, N.; Nellessen, N.; Dronse, J.; Dillen, K.; Jacobs, H. I.L.; Langen, K.-J.; Dietlein, M.; Kracht, L.; Neumaier, B.; Fink, G. R. et al.; Kukolja, J.; Onur, O. A.: Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD. NeuroImage: Clinical 24, 101978 (2019)

Zlatopolskiy, B. D.; Endepols, H.; Krapf, P.; Guliyev, M.; Urusova, E. A.; Richarz, R.; Hohberg, M.; Dietlein, M.; Drzezga, A.; Neumaier, B.: Discovery of F-18-JK-PSMA-7, a PET probe for the detection of small PSMA-positive lesions. Journal of Nuclear Medicine 60 (6), S. 817 - 823 (2019)

Richter, N.; Beckers, N.; Onur, O. A.; Dietlein, M.; Tittgemeyer, M.; Kracht, L. W.; Neumaier, B.; Fink, G. R.; Kukolja, J.: Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease. Brain 141 (3), S. 903 - 915 (2018)

Richter, N.; Michel, A.; Onur, O. A.; Kracht, L. W.; Dietlein, M.; Tittgemeyer, M.; Fink, G. R.; Kukolja, J.: White matter lesions and the cholinergic deficit in aging and mild cognitive impairment. Neurobiology of Aging 53, S. 27 - 35 (2017)

Richter, N.; Allendorf, I.; Onur, O. A.; Kracht, L. W.; Dietlein, M.; Tittgemeyer, M.; Neumaier, B.; Fink, G. R.; Kukolja, J.: The integrity of the cholinergic system determines memory performance in healthy elderly. NeuroImage 100 (Oct.), S. 481 - 488 (2014)

Kahraman, D.; Holstein, A.; Scheffler, M.; Zander, T.; Nogova, L.; Lammertsma, A. A.; Boellaard, R.; Neumaier, B.; Dietlein, M.; Wolf, J. et al.; Kobe, C.: Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clinical Nuclear Medicine 37 (11), S. 1058 - 1064 (2012)

Kobe, C.; Scheffler, M.; Holstein, A.; Zander, T.; Nogova, L.; Lammertsma, A. A.; Boellaard, R.; Neumaier, B.; Ullrich, R. T.; Dietlein, M. et al.; Wolf, J.; Kahraman, D.: Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging 39 (7), S. 1117 - 1127 (2012)

Scheffler, M.; Kobe, C.; Zander, T.; Nogova, L.; Kahraman, D.; Thomas, R. K.; Neumaier, B.; Dietlein, M.; Wolf, J.: Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET. Lung Cancer 77 (3), S. 617 - 620 (2012)

Kahraman, D.; Scheffler, M.; Zander, T.; Nogova, L.; Lammertsma, A. A.; Boellaard, R.; Neumaier, B.; Ullrich, R. T.; Holstein, A.; Dietlein, M. et al.; Wolf, J.; Kobe, C.: Quantitative analysis of response to treatment with Erlotinib in advanced non–small cell lung cancer using 18F-FDG and 39-deoxy-39-18F-fluorothymidine PET. Journal of Nuclear Medicine 52 (12), S. 1 - 7 (2011)

Zander, T.; Scheffler, M.; Nogova, L.; Kobe, C.; Engel-Riedel, W.; Hellmich, M.; Papachristou, I.; Toepelt, K.; Draube, A.; Heukamp, L. et al.; Buettner, R.; Ko, Y. D.; Ullrich, R. T.; Smit, E.; Boellaard, R.; Lammertsma, A. A.; Hallek, M.; Jacobs, A. H.; Schlesinger, A.; Schulte, K.; Querings, S.; Stoelben, E.; Neumaier, B.; Thomas, R. K.; Dietlein, M.; Wolf, J.: Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [ 18F] fluorothymidine positron emission tomography. Journal of Clinical Oncology 29 (13), S. 1701 - 1708 (2011)

Nogova, L.; Boellaard, R.; Kobe, C.; Hoetjes, N.; Zander, T.; Gross, S. H.; Dimitrijevic, S.; Pellas, T.; Eschner, W.; Schmidt, K. et al.; Bangard, C.; Hayes, W.; Thomas, R. K.; Dietlein, M.; Giaccone, G.; Hoekstra, O. S.; Lammertsma, A. A.; Wolf, J.: Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. Journal of Nuclear Medicine 50 (11), S. 1815 - 1819 (2009)